Abbvie's Future: Can It Weather The Litigation Storm?

AbbVie, a research-based biopharmaceutical company, has faced numerous lawsuits over some of its largest-selling products. These include testosterone replacement products, such as AndroGel, which has been linked to severe side effects and even deaths, resulting in personal injury and wrongful death lawsuits. AbbVie's blockbuster drug Humira has also been the subject of lawsuits, with claims of fungal infections, nerve damage, and increased cancer risk in children and adolescents. In addition, the company has been accused of aggressive marketing tactics and downplaying the risks associated with its products. AbbVie has also been involved in lawsuits with competitors, such as Genmab, over allegations of trade secret misappropriation. With operations in 170 countries and 50,000 employees, AbbVie's ability to survive these numerous lawsuits remains to be seen, although the company has already settled some cases and denied wrongdoing in others.

AbbVie's Humira drug

AbbVie, a research-based biopharmaceutical company, has faced numerous lawsuits over the years, including those related to its blockbuster drug Humira. Humira, a biologic medication, has been a global success for AbbVie, bringing in nearly $20 billion in sales across 60 markets and treating conditions such as arthritis, psoriasis, Crohn's disease, and ulcerative colitis. However, the drug has also been at the centre of several lawsuits, with patients blaming it for fungal infections, nerve damage, and an increased risk of cancer in children and adolescents. In one case, a jury ordered AbbVie to pay $2.24 million to a patient who suffered a fungal infection.

In addition to the lawsuits related to Humira, AbbVie has also faced legal challenges involving testosterone replacement therapy products, with more than 7,750 men filing lawsuits as of June 2018. The company has also been involved in lawsuits against competitors, alleging misappropriation of trade secrets by former employees. For instance, AbbVie sued Genmab, claiming that they turned a blind eye to trade secret theft related to technology for building antibody-drug conjugates (ADCs). AbbVie has also taken legal action against Adcentrx Therapeutics, alleging that they hired a former AbbVie scientist to obtain information about an antibody cancer program.

Despite the numerous lawsuits, AbbVie has continued to thrive as a global pharmaceutical company. The company has aggressively blocked competition and maintained high prices for Humira, which has contributed to its success. However, this strategy has also been criticised for hindering drug innovation and driving up costs for consumers. AbbVie has also been accused of exploiting its patient assistance programs, filing lawsuits against companies that help health plan sponsors take advantage of assistance programs providing specialty medicines to patients for free.

Testosterone replacement products

AbbVie is a research-based biopharmaceutical company that was formed in 2013 as a spin-off of Abbott Laboratories. The company has had a successful start, with its drug Humira bringing in billions. However, AbbVie has also faced lawsuits over some of its largest-selling products, including Humira and AndroGel, a testosterone replacement product.

In 2011, AbbVie predecessor Abbott Laboratories sued generic drug maker Perrigo to prevent them from bringing a generic version of AndroGel to market. The lawsuit was deemed a sham by U.S. District Judge Harvey Bartle, who concluded that it was a tactic to squelch competition for testosterone gel. As a result, AbbVie ended up paying Perrigo $2 million and granting them a license to sell a competing testosterone gel.

In 2018, AbbVie faced over 600 lawsuits related to its testosterone replacement products, with more than 7,750 men filing testosterone lawsuits against the company and other manufacturers of testosterone replacement therapy products. Many of these lawsuits blame testosterone replacement products for causing fungal infections, nerve damage, and an increased risk of cancer in children and adolescents.

In addition to the lawsuits related to its testosterone replacement products, AbbVie has also been involved in legal disputes with other companies over trade secret theft and patient assistance programs. Despite the numerous lawsuits, AbbVie has continued to operate and generate revenue from its products, including its testosterone replacement therapies. The company provides product information and support to healthcare professionals, patients, and caregivers through its website and medical information team.

Trade secret theft

AbbVie, a research-based biopharmaceutical company, has been involved in numerous lawsuits over the years, including those related to trade secret theft. One notable case involves the company's accusations against its partner, Genmab, for allegedly misappropriating trade secrets. AbbVie claimed that Genmab turned a blind eye to trade secret theft related to technology used in building antibody-drug conjugates (ADCs). The lawsuit named several former AbbVie employees and Tae Han, the founder of ProfoundBio, which was acquired by Genmab. AbbVie argued that Genmab should have known that ProfoundBio was built on its trade secrets.

In another instance, AbbVie sued rival BeiGene, accusing them of stealing trade secrets to develop a competing cancer drug. The trade secrets in question pertained to a medicinal chemical compound known as a Bruton's tyrosine kinase (BTK) degrader, which AbbVie was developing as a potential treatment for blood cancers. AbbVie alleged that a former employee, Huaqing Liu, disclosed these trade secrets to BeiGene when he joined their company.

Additionally, AbbVie has been involved in legal disputes with Adcentrx Therapeutics, Alvotech, and Revance, accusing them of similar instances of trade secret misappropriation by former AbbVie employees. These lawsuits highlight the challenges faced by AbbVie in protecting its intellectual property and competitive advantage in the highly competitive pharmaceutical industry.

While AbbVie has faced multiple lawsuits, it is important to note that the company has also initiated legal actions to protect its interests, as evidenced by the trade secret theft cases mentioned above. The outcome of these lawsuits can have significant implications for the company's reputation and future operations.

Improper marketing

AbbVie, a research-based biopharmaceutical company, has faced a multitude of lawsuits since its founding in 2013. One of the prominent issues that have plagued the company is improper marketing.

AbbVie has been aggressive in its marketing strategies, spending a massive $145 million on doctor marketing and promotion, the largest amount by a pharmaceutical company since federal Open Payments data became available in 2017. This spending includes compensation for consulting, speaking fees, lodging, travel, and meals for doctors, as well as payments to hospitals. Such aggressive targeting of doctors by AbbVie has raised concerns among competitors and the medical community.

The company's blockbuster drug, Humira, has been at the center of controversy, with numerous lawsuits blaming the drug for adverse effects, including fungal infections, nerve damage, and an increased risk of cancer in children and adolescents. In 2013, AbbVie was ordered to pay $2.24 million to a patient who suffered a fungal infection due to Humira. Additionally, more than 7,750 men have filed testosterone lawsuits against AbbVie and other manufacturers of testosterone replacement therapy products, with nearly 6,000 cases still pending as of June 2018.

In addition to lawsuits from consumers, AbbVie has also faced legal challenges from competitors alleging misappropriation of trade secrets. In one case, AbbVie accused Genmab, a partner company, of turning a blind eye to trade secret theft related to technology for building ADCs. The lawsuit named several former AbbVie employees and highlighted the competitive nature of the industry.

Despite the numerous lawsuits, AbbVie has demonstrated resilience and a commitment to innovation. The company continues to discover and deliver new medicines and solutions to address complex health issues. However, the impact of these lawsuits on AbbVie's long-term survival remains to be seen, especially as the company navigates increased scrutiny and public awareness of its products and practices.

Corporate record protection

Corporate record-keeping is a systematic practice of documenting and organizing a company's important information and transactions. It is a vital aspect of compliance and facilitates informed decision-making. Corporate records are required to show that a company is functioning according to regulatory rules. They also provide liability protection by demonstrating that a company is a separate entity with its own governance processes.

There are various types of corporate records, including tax forms, annual reports, business ledgers, tax returns, meeting minutes, bylaws, resolutions, and bank statements. These records are created by different members of the corporation, such as the board of directors, corporate secretary, and accountants. While some records, like articles of incorporation, remain relatively static, others, like bylaws, may evolve with the organization. It is essential to establish a retention schedule that dictates how long different types of records should be kept and how to dispose of them when they are no longer needed. For example, tax returns usually need to be kept for six years, while corporate tax records must be retained for seven years, according to the IRS.

In today's virtual working environment, companies are shifting from traditional physical record-keeping to electronic files. However, regardless of the method chosen, it is crucial to ensure that records are organized, thorough, and protected. Backing up records is essential to prevent loss or damage, as paper files are vulnerable to physical hazards like fire and water damage, while electronic files can be deleted or lost due to technical failures.

Proper corporate record-keeping is essential to maintain personal liability protection for shareholders, members, and management. Neglecting record-keeping can result in serious legal repercussions, as evidenced by the "piercing the corporate veil" concept, where a company's separate legal entity status may be challenged if its actions are not adequately documented.

In summary, corporate record protection involves the systematic documentation and organization of a company's vital information. It ensures compliance, facilitates decision-making, and provides liability protection. By establishing comprehensive record-keeping practices, companies can maintain control over their data, comply with regulatory requirements, and protect themselves from legal risks.

Frequently asked questions